Yazar "Toka, Onur" seçeneğine göre listele

Listeleniyor 1 - 2 / 2
  • Küçük Resim Yok
    Öğe
    Awareness of Hepatitis B virus reactivation among physicians administering immunosuppressive treatment and related clinical practices
    (AVES, 2019) Korkmaz, Pınar; Demirtürk, Neşe; Aydın, Gule; Çeken, Sabahat; Aygen, Bilgehan; Toka, Onur; Gündoğdu, Kıymet; Çelikbaş, Aysel Kocagül; İnan, Dilara; Kuruüzüm, Ziya; Kutsoylu, Oya Özlem Eren; Batırel, Ayşe; Sırmatel, Fatma; Ersöz, Gülden; Hakyemez, İsmail Necati; Aşçı, Zerrin; Yeşilbağ, Zuhal; Sönmezer, Meliha Çağla; Tülek, Necla; Örmen, Bahar; Karadağ, Fatma Yılmaz; Yörük, Gülşen; Türker, Nesrin; Özkaya, Hacer Deniz; Kalkan, İrem Akdemir; Süer, Hüseyin Kaya; Tekin, Süda; Saltoğlu, Neşe; Şener, Alper; Yenilmez, Ercan; Çetinkaya, Rıza Aytaç; Özel, Selcan Arslan; Ayaz, Celal; Karagöz, Ergenekon; Aydın, Mehtap; Acar, Ali; Arslan, Eyüp; Ceylan, Mehmet Reşat; Demir, Nazlım Aktuğ; Çaylak, Selmin Dirgen; Günal, Özgür; Solay, Aslı Haykır; Öztürk, Sinan; Ural, Onur; Sümer, Şua; Kadanalı, Ayten; Altıparmak, Vuslat Ecem Güneş; Akhan, Sıla; Sayan, Murat; Köse, Şükran
    Objective: This study aimed to evaluate the awareness and knowledge levels of all physicians administering immunosuppressive treatment concerning hepatitis B virus (HBV) reactivation, and draw attention to the importance of the subject through evaluation. Methods: The study was carried out by infectious diseases and clinical microbiology specialists in 37 health centers, and it was performed in Turkey between January and March 2017. All specialists providing a written consent and working in the departments of Medical Oncology, Hematology, Dermatology and Venereology, Physical Medicine and Rehabilitation, and Rheumatology of each study center were included in the study. Results: A total of 430 physicians participated in the study. Their mean age was 39.87 +/- 7.42 years, and 47.9% of them were males. During their career, 39.3% of these physicians had encountered patients developing HBV reactivation while receiving immunosuppressive treatment. The rate of encountering patients who died due to HBV reactivation was 6.5%. 97% of physicians who participated, considered the risk of HBV reactivation to be important. 70.2% of physicians stated that guidelines related to HBV reactivation and antiviral treatment for these patients were discussed in the congresses they participated, regarding their specialties. The rate of performing hepatitis screening among physicians whose patients developed HBV reactivation was statistically significantly higher than those physicians who had no patients with HBV reactivation (p<0.05). Physicians who used the guidelines related to HBV reactivation in their specialties performed screening for the HBV infection much more often than physicians who did not use the guidelines (p=0.002). Conclusions: According to the results obtained in our study, the rates of conducting screening and awareness of HBV reactivation among physicians administering immunosuppressive treatment were higher compared with similar studies; however, their awareness that HBV DNA and anti-HBc should be utilized much more frequently among the serological tests they use for screening of HBV infection, should be increased.
  • Küçük Resim
    Öğe
    Hepatosteatozun entekavir ve tenofovir tedavilerinde virolojik yanıta etkisi
    (AVES, 2019) Korkmaz, Pınar; Demirtürk, Neşe; Batırel, Ayşe; Tülek, Necla; Özgüler, Müge; Harman, Rezan; Çınar, Güle; Toka, Onur; Yörük, Gülşen; Hatipoğlu, Çiğdem Ataman; Sarıgül, Figen; Sırmatel, Fatma; İmre, Ayfer; Özatağ, Duru Mıstanoğlu; Karakeçili, Faruk; Ural, Onur; Sümer, Şua; Demir, Nazlım Aktuğ; Kadanalı, Ayten; Çomoğlu, Şenol; Üçer, Sengül; Saltoğlu, Neşe; Günal, Özgür; Özkaya, Hacer Deniz; Yenilmez, Ercan; Çetinkaya, Rıza Aytaç; Yüksel, Esma; Hakyemez, İsmail Necati; Meriç-Koç, Meliha; Tuncer-Ertem, Günay; Dursun, Zehra Beştepe; Çelik, İlhami; Yılmaz, Emel; Evik, Güliz; Kaya, Ali; Süer, Kaya
    Objective: Both chronic hepatitis B (CHB) and hepatosteatosis may lead to necroinflammation in liver. Therefore, the presence of hepatosteatosis might negatively affect the efficacy of antiviral therapy. We aimed to determine the effect of hepatosteatosis on virological response in patients with CHB receiving entecavir (ETV) and tenofovir (TDF) treatment. Methods: The study was designed retrospectively. All patients receiving antiviral therapy due to CHB in the departments of Infectious Diseases and Clinical Microbiology of 29 different hospitals between January 2012 and June 2017 were searched by examining medical records. Results: A total of 1069 patients were included. Six hundred and fifty of the patients had been receiving TDF and 419 of them had been receiving ETV. The rate of virological response obtained at the 48'h week of TDF was higher in patients with steatosis (p=0.029). Virological response at the 24th week and 48th week of ETV were higher in the patients without steatosis (p=0.001). TDF and ETV therapies were compared in the patients with hepatosteatosis and it was found that the virological response at 48th week was higher in the TDF group. Conclusion: Although steatosis has an effect on virological response in the short-term results of nucleos(t)ide therapy, it does not have any effect on virological response in the long-term results.